Granted patents & published patent applications 

  1. Antihistamines in combination with a range of substance for improved health. Knutsen, L.J.S.; Knutsen, J.L.; Pimley, M.A. (Requis Pharmaceuticals Inc.). PCT Int. Appl. (2015), WO 2015/089489 A1, 18 June 2015.
  2. Preparations for the treatment of sleep-related breathing disorders. Knutsen, L.J.S.; Hand, J.M. (Requis Pharmaceuticals Inc.). PCT Int. Appl. (2014), WO 2014/138162 A1, 12 September 2014.
  3. Method for the Treatment of Neuropathies associated with Charcot-Marie-Tooth 1A (CMT1A) Disease. Inglese, J.; Svaren, J.P. Jang, S-W.; Scheideler, M.A.; Knutsen, L.J.S. (National Institutes of Health, US Dept. of Health and Human Services and Charcot-Marie-Tooth Association) PCT Int. Appl. (2014), US 2014/0080787 A1, 20 March 2014.
  4. Pyridazinone derivatives. Bacon, E.R.; Bailey, T.R.; Becknell, N.C.; Chatterjee, S.; Dunn, D.; Hostetler, G.A.; Hudkins, R.L.; Josef, K.A.; Knutsen, L.J.S.;  Tao, M.;  Zulli, A.L. (Cephalon, Inc.). U.S. Pat. Appl. Publ. (2014),  US 20140142088 A1, 22 May 2014.
    Combination nutritional and nutraceutical products.  Knutsen, J.L.; Knutsen, L.J.S. (Requis Pharmaceuticals Inc.). PCT Int. Appl. (2013), WO 2013/074531 A1, 23 May 2013.
  5. Antihistamines combined with dietary supplements for improved health.  Knutsen, L.J.S.; Knutsen, J.L. (Discovery Pharma Consulting LLC). U.S. Pat. Appl. Publ. (2012), 20120170883 A1, December 13, 2012.
  6. Pyridazinone Derivatives. Bacon, E.R.; Bailey, T.R.; Becknell, N.C.; Chatterjee, S.; Dunn, D.; Hostetler, G.A.; Hudkins, R.L.; Josef, K.A.; Knutsen, L.J.S.;  Tao, M.;  Zulli, A.L. (Cephalon, Inc.). U.S. Pat. Appl. Publ. (2011), 20110288075 A1, November 24, 2011.
  7. Substituted pyridazine derivatives. Hudkins, R.L.; Knutsen, L.J.S.; Prouty, C.P.; Sundar, B.G.; Wells-Knecht, K.J. (Cephalon, Inc.).  U.S. Pat. Appl. Publ. (2010), 20100311752 A1, December 9, 2010.
  8. Pyridazinone Derivatives. Bacon, E.R.; Bailey, T.R.; Becknell, N.C.; Chatterjee, S.; Dunn, D.; Hostetler, G.A.; Hudkins, R.L.; Josef, K.A.; Knutsen, L.J.S.;  Tao, M.;  Zulli, A.L. (Cephalon, Inc.). U.S. Pat. Appl. Publ. (2010), US 20100280007 A1, 4 November, 2010.
  9. Pyridazinone Derivatives. Bacon, E.R.; Bailey, T.R.; Becknell, N.C.; Chatterjee, S.; Dunn, D.; Hostetler, G.A.; Hudkins, R.L.; Josef, K.A.; Knutsen, L.J.S.;  Tao, M.;  Zulli, A.L. (Cephalon, Inc.). U.S. Pat. Appl. Publ. (2010), US 20100273779 A1, 28 October 2010.
  10. Substituted pyridazine derivatives which have histamine H3 antagonist activity.  Hudkins, R.L.; Knutsen, L.J.S.; Prouty, C.P.; Sundar, B.G.; Wells-Knecht, K.J. (Cephalon, Inc.). PCT Int. Appl. (2009), WO 09/97306 A1, 6 August 2009.
  11. Azacyclic compounds as inhibitors of sensory neuron specific channels (SNS). Hamlyn, R.; Huckstep, M.; Earnshaw, C.G.; Stokes, S.; Tickle, D.; Allart, B.; Boyd, J.W.; Knutsen, L.J.S.; Lynch, R.; Patient, L. (Ionix Pharmaceuticals Limited, UK). PCT Int. Appl. (2006), WO 06/082354 A1, 8 August 2006.
  12. Preparation of acyclic sulfonamides as N-type calcium channel antagonists. Hobbs, C.J.; Lynch, R.; Mellor, S.L.; Radford, F.; Gilbert, J.C.; Stokes, S.; Glen, A.; Fiumana, A.; Earnshaw, C.G.; Knutsen, L.J.S.; Dean, K.E.S. (Ionix Pharmaceuticals Limited, UK). PCT Int. Appl.  (2006), WO 06/030211 A2 23 March 2006.
  13. Sulfonamides, particularly N-(phenylsulfonyl)piperidines, as N-type calcium channels antagonists useful for treatment of pain and their preparation. Radford, F.; Lynch, R., Mellor, S. L.; Hobbs, C.J.; Gilbert, J.C.; Stokes, S.; Glen, A.; Fiumana, A.; Smith, N.J; Earnshaw, C.G.; Knutsen, L.J.S. (Ionix Pharmaceuticals Limited, UK).  PCT Int. Appl.  (2005), WO 05/068448 A1 28 July 2005.
  14. Preparation of benzene and phenol derivatives as inhibitors of sensory neuron specific (SNS) sodium channels. Jennings, N.S.; Stokes, S.; Hamlyn, R.J.; Tickle, D.C.; Huckstep, M. R.; Lynch, R.; Knutsen, L.J.S. (Ionix Pharmaceuticals Limited., UK). PCT Int. Appl. (2005), WO 05/00309 A2 06 January 2005.
  15. 1,3-Thiazolin-4-ones as therapeutic compounds in the treatment of pain.  Knutsen, L.J.S; Hobbs, C.J.; Radford, F.; Fiumana, A. (Ionix Pharmaceuticals Limited, UK). PCT Int. Appl. (2004) WO 04/17965 A1 04 March 2004.
  16. Five-membered heterocyclic compounds in the treatment of chronic and acute pain.  Knutsen, L.J.S.; Hobbs, C.J.; Radford, F.; Fiumana, A.; Earnshaw, C.G.; Mellor, S.L.; Smith, N.J. (Ionix Pharmaceuticals Limited, UK). PCT Int. Appl. (2004), WO 04/17966 A1 04 March 2004.
  17. Preparation of 4-quinolinemethanol derivatives as purine receptor antagonists. (II).  Gillespie, R. J.; Lerpiniere, J.; Giles, P.R.; Adams, D.R.; Knutsen, L..J.S.; Cliffe, I.A. (Cerebrus Ltd. UK) PCT Int. Appl.  (2000), 73 pp.  WO 00/13682 A2, 16 March 2000.
  18. Preparation of 4-quinolinemethanol derivatives as purine receptor antagonists. Gillespie, R.J.; Lerpiniere, J.; Gaur, S.; Adams, D.R.; Knutsen, L.J.S.; Ward, S.E. (Cerebrus Ltd. UK) PCT Int. Appl.  (2000), 76 pp.  WO 00/13681 A2, 16 March 2000.
  19. Novel pyridine and pyrimidine derivatives.  Knutsen, L.J.S.; Lundemose, A.G.; Jeppesen, C.B.; Sorensen, A.R.; Danielsen, G.M. (Novo Nordisk A/S, Den.) WO 99/31098 A1, June 24, 1999.
  20. (-)-Mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders.  Shepherd, R.; Knutsen, L.J.S.; Porter, R.H.P.; Weiss, S.M. (Cerebrus Ltd. UK) WO 99/26627, 03 June 1999.
  21. Preparation of novel halo-N-[(heterocyclyl)thio-1-piperidinyl]adenosines as A1 receptor agonists.  Knutsen, Lars.  (Novo Nordisk A/S, Den.)  WO 9816539 A1, 23 April 1998.
  22. Prepn. of nucleosides for treating disorders related to cytokines in mammals.  Knutsen, L.; Olsen, U.B.; Bowler, A.N. (Novo Nordisk A/S, Den.). PCT Int. Appl., 78 pp. WO97/33591A1 18 Sept 1997.
  23. Preparation of N-alkoxyadenosines as cytokine inhibitors.  Knutsen, L.; Olsen, U.B.; Roberts, S.M.; Varley, D.R.; Bowler, A.N. (Novo Nordisk A/S, Den.). PCT Int. Appl., 70 pp. WO 98/01459 A1 15 January 1998.
  24. Preparation of novel halo-N-[(heterocyclyl)thio-1-piperidinyl]adenosines as A1 receptor agonists.  Knutsen, L. (Novo Nordisk A/S, Den.) WO 98/16539 A1, 23 April 1998.
  25. Preparation of adenosine derivatives for treatment of central nervous system diseases.  Lau, J.; Knutsen, L.J.S. (Novo Nordisk A/S, Den.). PCT Int. Appl., 62 pp.  WO 95/07921 A1 23 March 1995.
  26. Preparation of N-(heterocyclylalkyl)purine derivatives as adenosine A1 agonists. Lau, J.; Knutsen, L.J.S.; Sheardown, M.; Hansen, A.J. (Novo Nordisk A/S, Den.).  PCT Int. Appl., 68 pp.  WO 94/14832 A1 7 July 1994.
  27. Purine derivatives. Knutsen, L.J.S; Lau, J. (Novo Nordisk A/S, Den.). PCT Int. Appl., 49 pp. WO 93/23418 A1 25 November 1993.
  28. Adenosine derivatives. Knutsen, L.J.S.; Lau, J. (Novo Nordisk A/S, Den.). PCT Int. Appl., 39 pp. WO 93/23417 A1 25 November 1993.
  29. Preparation of 2,6-disubstituted purine nucleoside anticonvulsants.  Knutsen, L.J.S; Lau, J. (Novo Nordisk A/S, Den.). PCT Int. Appl., 51 pp. WO 93/08206 A1 29 May 1993.
  30. Novel heterocyclic carboxylic acids. Andersen, K.E; Knutsen, L.J.S; Soerensen, P.O; Lundt, B.F.; Lau, J.; Petersen, H. (Novo Nordisk A/S, Den.). PCT Int. Appl., 58 pp. WO 92/20658 A1 26 November 1992.
  31. Preparation of N-[2-(3,3-diphenylpropoxy)ethyl]piperidine-3-carboxylates and analogs as GABA uptake inhibitors.  Andersen, K.E; Knutsen, L.J.S; Sonnewald, U.; Soerensen, P.O. (Novo-Nordisk A/S, Den.).  PCT Int. Appl., 63 pp.  WO 9107389 A1 30 May 1991.
  32. Preparation of N-(aralkoxyalkyl)piperidinecarboxylates and analogs as GABA-uptake inhibitors.  Knutsen, L.J.S; Jorgensen, A.S; Andersen, K.E; Sonnewald, U. (Novo-Nordisk A/S, Den.). Eur. Pat. Appl., 25 pp.  EP 374801 A2 27 June 1990.
  33. Azacyclic carboxylic acid derivatives, their preparation and use as GABAergic agonist pharmaceuticals.  Knutsen, L.J.S.; Andersen, K.E; Jorgensen, A.S; Sonnewald, U. (Novo Industri A/S, Den.).  Eur. Pat. Appl., 26 pp.  EP 342635 A1 23 November 1989.
  • Of these patents & patent applications, 24 are issued in the USA:
  1. US 9,700,548 Antihistamines Combined with Dietary Supplements for Improved Heath
  2. US 8,673,916 Methods of Treating Disorders Mediated by Histamine H3 receptors using Pyridazinone Derivatives
  3. US 8,586,588 Aryl Pyridazinone Derivatives and their use as H3 receptor ligands
  4. US 8,247,414 Pyridizinone derivatives and the use thereof as H3 inhibitors
  5. US 8,207,168 Pyridazinone derivatives
  6. US 8,076,331 Substituted Pyridazine derivatives
  7. US 6,608,085 4-Quinolinemethanol derivatives as purine receptor antagonists (II)
  8. US 6,583,156 4-Quinolinemethanol derivatives as purine receptor antagonists (I)
  9. US 6,197,788 (-)-Mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
  10. US 5,683,989 Treatment of ischemias by administration of 2,N.sup.6 -substituted adenosines
  11. US 5,672,588 Purine derivatives
  12. US 5,589,467 2,5′,N6-trisubstituted adenosine derivatives
  13. US 5,578,582 Methods of treating ischemia with C2, N6 -disubstituted adenosine derivatives
  14. US 5,484,774 2, N6 -disubstituted adenosines, tri-O-ester derivatives and their pharmaceutical compositions to treat ischemias
  15. US 5,432,164 C2,N6 -disubstituted adenosine derivatives
  16. US 5,430,027 2-Chloro-N6 -substituted adenosines, their pharmaceutical compositions, and activity in treating ischemias
  17. US 5,348,965 N-substituted azaheterocyclic carboxylic acids
  18. US 5,231,106 Azacyclic carboxylic acid derivatives and their preparation and use
  19. US 5,229,404 Azacyclic carboxylic acid derivatives and their preparation and use
  20. US 5,214,057 N-substituted azaheterocyclic carboxylic acids
  21. US 5,214,054 Azacyclic carboxylic acid derivatives and their preparation and use
  22. US 5,198,451 Heterocyclic carboxylic acids
  23. US 5,071,859 N-substituted azaheterocyclic carboxylic acids and pharmaceutical uses
  24. US 5,039,685 Azacyclic carboxylic acid derivatives, their preparation and use

Leave a Reply

Your email address will not be published. Required fields are marked *